Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole-body Hyperthermia in Advanced Solid Cancer and Metastatic Pancreatic Cancer
NCT04467593Completed
- Sponsor
- ElmediX
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Open-label trial in malignant solid tumor and pancreatic cancer (PC) (5 cohorts), sponsored by ElmediX. Primary endpoints: Safety of WBHT at 41.50 °C in Combination With Chemotherapy and Tolerability of WBHT at 41.50 °C in Combination With Chemotherapy. Started Jul 2021; status: completed.
02
Conditions
malignant solid tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04467593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467593.